SG11202100076RA - Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same - Google Patents
Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the sameInfo
- Publication number
- SG11202100076RA SG11202100076RA SG11202100076RA SG11202100076RA SG11202100076RA SG 11202100076R A SG11202100076R A SG 11202100076RA SG 11202100076R A SG11202100076R A SG 11202100076RA SG 11202100076R A SG11202100076R A SG 11202100076RA SG 11202100076R A SG11202100076R A SG 11202100076RA
- Authority
- SG
- Singapore
- Prior art keywords
- preventing
- same
- pharmaceutical compositions
- cancers including
- treating cancers
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180086768A KR101954370B1 (ko) | 2018-07-25 | 2018-07-25 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| PCT/KR2019/001737 WO2020022600A1 (fr) | 2018-07-25 | 2019-02-13 | Composés pyrimidine et compositions pharmaceutiques pour la prévention ou le traitement de cancers les comprenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100076RA true SG11202100076RA (en) | 2021-02-25 |
Family
ID=65760263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100076RA SG11202100076RA (en) | 2018-07-25 | 2019-02-13 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11292786B2 (fr) |
| EP (1) | EP3810601A4 (fr) |
| JP (1) | JP6806931B2 (fr) |
| KR (1) | KR101954370B1 (fr) |
| CN (2) | CN112469715B (fr) |
| AR (1) | AR119657A1 (fr) |
| BR (1) | BR112021001122A2 (fr) |
| CA (1) | CA3106961A1 (fr) |
| CL (1) | CL2021000175A1 (fr) |
| DO (1) | DOP2021000017A (fr) |
| MX (1) | MX2021000941A (fr) |
| PE (1) | PE20210373A1 (fr) |
| PH (1) | PH12021550124A1 (fr) |
| SG (1) | SG11202100076RA (fr) |
| TW (1) | TWI839363B (fr) |
| WO (1) | WO2020022600A1 (fr) |
| ZA (1) | ZA202100485B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020171646A1 (fr) * | 2019-02-22 | 2020-08-27 | 한미약품 주식회사 | Composition pharmaceutique comprenant un inhibiteur flt3 et un agent hypométhylant pour le traitement de la leucémie myéloïde aiguë |
| JP2022538817A (ja) * | 2019-06-27 | 2022-09-06 | ハンミ ファーマシューティカル カンパニー リミテッド | Ｆｌｔ３阻害剤および化学療法剤を含む急性骨髄白血病を治療するための薬学的組成物 |
| WO2021066443A1 (fr) * | 2019-09-30 | 2021-04-08 | 한미약품 주식회사 | Composition pharmaceutique pour le traitement de la leucémie aiguë myéloïde contenant un inhibiteur de flt3 et un inhibiteur de mdm2 |
| KR20220061026A (ko) * | 2020-11-05 | 2022-05-12 | 한미약품 주식회사 | Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물 |
| TW202246243A (zh) * | 2021-02-26 | 2022-12-01 | 美商泰拉生物科學公司 | 胺基嘧啶化合物及其使用方法 |
| WO2022216098A1 (fr) * | 2021-04-08 | 2022-10-13 | 주식회사 스탠다임 | Nouvel inhibiteur de lrrk2 |
| WO2023027966A1 (fr) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Composés de pyrazine en tant qu'inhibiteurs irréversibles de flt3 |
| KR20230056331A (ko) * | 2021-10-20 | 2023-04-27 | 한미약품 주식회사 | 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합 |
| US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
| WO2023225005A1 (fr) | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Polythérapie à base de flt3 pour le cancer et compositions associées |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| CA2702126A1 (fr) | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Antagonistes des canaux calciques de type t a base d'amide heterocyclique |
| FR2926553B1 (fr) | 2008-01-23 | 2010-02-19 | Sanofi Aventis | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique |
| US20110183975A1 (en) * | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| MX2012000709A (es) * | 2009-07-15 | 2012-03-16 | Abbott Lab | Inhibidores de pirrolopiridina de cinasas. |
| HUE032515T2 (en) * | 2010-06-23 | 2017-09-28 | Hanmi Science Co Ltd | New condensed pyrimidine derivatives for inhibiting tyrosine kinase activity |
| TW201219383A (en) * | 2010-08-02 | 2012-05-16 | Astrazeneca Ab | Chemical compounds |
| WO2014155300A2 (fr) * | 2013-03-28 | 2014-10-02 | Aurigene Discovery Technologies Limited | Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1 |
| MX358346B (es) * | 2014-04-04 | 2018-08-15 | Syros Pharmaceuticals Inc | Inhibidores de la quinasa dependiente de ciclina 7 (cdk7). |
| ES2805976T3 (es) | 2016-06-30 | 2021-02-16 | Janssen Pharmaceutica Nv | Derivados heteroaromáticos en calidad de inhibidores de NIK |
| EA039868B1 (ru) * | 2017-01-26 | 2022-03-22 | Ханми Фарм. Ко., Лтд. | Пиримидиновое соединение и его фармацевтическое применение |
-
2018
- 2018-07-25 KR KR1020180086768A patent/KR101954370B1/ko active IP Right Grant
-
2019
- 2019-02-13 MX MX2021000941A patent/MX2021000941A/es unknown
- 2019-02-13 JP JP2019566602A patent/JP6806931B2/ja active Active
- 2019-02-13 CA CA3106961A patent/CA3106961A1/fr active Pending
- 2019-02-13 WO PCT/KR2019/001737 patent/WO2020022600A1/fr active Application Filing
- 2019-02-13 SG SG11202100076RA patent/SG11202100076RA/en unknown
- 2019-02-13 EP EP19841611.7A patent/EP3810601A4/fr active Pending
- 2019-02-13 PE PE2021000090A patent/PE20210373A1/es unknown
- 2019-02-13 CN CN201980049569.8A patent/CN112469715B/zh active Active
- 2019-02-13 BR BR112021001122-6A patent/BR112021001122A2/pt unknown
- 2019-02-13 CN CN202310204523.7A patent/CN116693506A/zh active Pending
- 2019-07-09 TW TW108124118A patent/TWI839363B/zh active
- 2019-07-24 AR ARP190102087A patent/AR119657A1/es unknown
-
2020
- 2020-04-27 US US16/859,413 patent/US11292786B2/en active Active
-
2021
- 2021-01-15 PH PH12021550124A patent/PH12021550124A1/en unknown
- 2021-01-22 ZA ZA2021/00485A patent/ZA202100485B/en unknown
- 2021-01-22 CL CL2021000175A patent/CL2021000175A1/es unknown
- 2021-01-22 DO DO2021000017A patent/DOP2021000017A/es unknown
-
2022
- 2022-01-25 US US17/583,841 patent/US20230002358A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020022600A1 (fr) | 2020-01-30 |
| AR119657A1 (es) | 2022-01-05 |
| TW202014417A (zh) | 2020-04-16 |
| JP6806931B2 (ja) | 2021-01-06 |
| CN116693506A (zh) | 2023-09-05 |
| EP3810601A1 (fr) | 2021-04-28 |
| KR101954370B1 (ko) | 2019-03-05 |
| CA3106961A1 (fr) | 2020-01-30 |
| DOP2021000017A (es) | 2021-04-15 |
| US11292786B2 (en) | 2022-04-05 |
| BR112021001122A2 (pt) | 2021-04-13 |
| MX2021000941A (es) | 2021-03-09 |
| EP3810601A4 (fr) | 2022-04-20 |
| CN112469715B (zh) | 2024-06-11 |
| ZA202100485B (en) | 2023-11-29 |
| JP2020527128A (ja) | 2020-09-03 |
| PE20210373A1 (es) | 2021-02-26 |
| US20200255410A1 (en) | 2020-08-13 |
| US20230002358A1 (en) | 2023-01-05 |
| TWI839363B (zh) | 2024-04-21 |
| CL2021000175A1 (es) | 2021-07-02 |
| PH12021550124A1 (en) | 2021-09-27 |
| CN112469715A (zh) | 2021-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202100076RA (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| EP3533466A4 (fr) | Composition pharmaceutique pour le traitement et/ou la prévention du cancer | |
| IL279347A (en) | Gremlin-1 antagonist for cancer prevention and treatment | |
| EP3858353A4 (fr) | Composition pharmaceutique pour prévenir et traiter la nitm et utilisation pharmaceutique associée | |
| IL263793A (en) | Compounds and preparations for the treatment of cancer | |
| EP3847283A4 (fr) | Composés, compositions et méthodes de traitement ou de prévention de cancers induits par her | |
| GB201819957D0 (en) | Novel quinazolinone derivatives inhibiting piek and pharmaceutical composition containing same | |
| IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
| IL276326A (en) | Dihydropyrimidinone or dihydrotriazinone compounds with a saturated compressed ring and their pharmaceutical use | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| IL279609A (en) | Bifunctional compounds for cancer treatment | |
| EP3689355A4 (fr) | Traitements pharmaceutiques pour prévenir ou traiter le cancer du foie | |
| IL284124A (en) | History of quinoline for use in the treatment or prevention of cancer | |
| EP3290051A4 (fr) | Composition pharmaceutique permettant le traitement et/ou la prévention du cancer | |
| PL3810128T3 (pl) | Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek | |
| EP3372233A4 (fr) | Composition pharmaceutique pour le traitement et/ou la prévention du cancer | |
| IL282692A (en) | Compounds derived from madrasin, a preparation and their uses for the treatment of cancer | |
| GB202001368D0 (en) | Pharmaceutical composition for preventing or treating cancer containign recepto tyrosine kinase inhibitor as active ingredient | |
| KR102483495B9 (ko) | 2,4-이치환된 피리미딘 유도체 및 이를 포함하는 약학적 조성물 | |
| PT3813832T (pt) | Compostos para utilização na prevenção ou tratamento de cancro | |
| EP3498284A4 (fr) | Composition pharmaceutique pour le traitement et/ou la prévention du cancer | |
| IL281782A (en) | Drug combination for cancer treatment | |
| EP3437656A4 (fr) | Composition pharmaceutique pour le traitement et/ou la prévention du cancer | |
| EP3437655A4 (fr) | Composition pharmaceutique pour le traitement et/ou la prévention du cancer | |
| EP3409281A4 (fr) | Composition pharmaceutique pour le traitement et/ou la prévention du cancer |